GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Shiller PE Ratio

Ascendis Pharma A/S (Ascendis Pharma A/S) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2015. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Shiller PE Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Ascendis Pharma A/S's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Shiller PE Ratio falls into.



Ascendis Pharma A/S Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ascendis Pharma A/S's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Ascendis Pharma A/S's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.679/116.7000*116.7000
=-1.679

Current CPI (Dec. 2023) = 116.7000.

Ascendis Pharma A/S Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.064 99.600 -0.075
201406 -0.269 99.700 -0.315
201409 -0.151 99.700 -0.177
201412 -0.367 99.400 -0.431
201503 0.065 100.200 0.076
201506 -0.707 100.300 -0.823
201509 -0.337 100.200 -0.392
201512 -0.534 99.800 -0.624
201603 -0.913 100.200 -1.063
201606 -0.596 100.600 -0.691
201609 -0.808 100.200 -0.941
201612 -0.538 100.300 -0.626
201703 -0.834 101.200 -0.962
201706 -1.056 101.200 -1.218
201709 -1.240 101.800 -1.421
201712 -1.089 101.300 -1.255
201803 -1.319 101.700 -1.514
201806 -0.643 102.300 -0.734
201809 -0.945 102.400 -1.077
201812 -0.865 102.100 -0.989
201903 -1.401 102.900 -1.589
201906 -1.412 102.900 -1.601
201909 -0.584 102.900 -0.662
201912 -1.889 102.900 -2.142
202003 -1.459 103.300 -1.648
202006 -2.218 103.200 -2.508
202009 -2.721 103.500 -3.068
202012 -3.212 103.400 -3.625
202103 -1.393 104.300 -1.559
202106 -3.012 105.000 -3.348
202109 -1.729 105.800 -1.907
202112 -2.113 106.600 -2.313
202203 -2.434 109.900 -2.585
202206 -1.543 113.600 -1.585
202209 -3.000 116.400 -3.008
202212 -3.919 115.900 -3.946
202303 -2.120 117.300 -2.109
202306 -2.340 116.400 -2.346
202309 -3.074 117.400 -3.056
202312 -1.679 116.700 -1.679

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (NAS:ASND) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ascendis Pharma A/S Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (Ascendis Pharma A/S) Headlines